Schöpf, Julia
Uhrig, Sebastian
Heilig, Christoph E. http://orcid.org/0000-0001-8869-1421
Lee, Kwang-Seok http://orcid.org/0000-0001-7682-5736
Walther, Tatjana
Carazzato, Alexander http://orcid.org/0009-0000-4353-0560
Dobberkau, Anna Maria
Weichenhan, Dieter
Plass, Christoph
Hartmann, Mark http://orcid.org/0000-0002-4072-4658
Diwan, Gaurav D.
Carrero, Zunamys I. http://orcid.org/0000-0001-8501-1566
Ball, Claudia R.
Hohl, Tobias http://orcid.org/0000-0002-2229-4391
Kindler, Thomas
Rudolph-Hähnel, Patricia
Helm, Dominic http://orcid.org/0000-0001-9321-2069
Schneider, Martin
Nilsson, Anna
Øra, Ingrid http://orcid.org/0000-0002-3931-4125
Imle, Roland http://orcid.org/0000-0001-9564-6952
Banito, Ana http://orcid.org/0000-0003-2188-0003
Russell, Robert B. http://orcid.org/0000-0002-1905-4717
Jones, Barbara C.
Lipka, Daniel B. http://orcid.org/0000-0001-5081-7869
Glimm, Hanno http://orcid.org/0000-0003-4104-1135
Hübschmann, Daniel http://orcid.org/0000-0002-6041-7049
Hartmann, Wolfgang http://orcid.org/0000-0002-7609-5021
Fröhling, Stefan http://orcid.org/0000-0001-7907-4595
Scholl, Claudia http://orcid.org/0000-0001-6768-322X
Article History
Received: 23 March 2023
Accepted: 11 December 2023
First Online: 2 January 2024
Competing interests
: The authors declare the following competing interests: C.E.H. has received research funding from AstraZeneca, Pfizer, PharmaMar, and Roche. I.Ø. has received funding from AstraZeneca and Pfizer. D.B.L. has received honoraria from Illumina and is an employee of Infectopharm. S.F. has had a consulting or advisory role and received honoraria, research funding, and/or travel/accommodation expenses funding from the following for-profit companies: Amgen, AstraZeneca, Bayer, Eli Lilly, Pfizer, PharmaMar, and Roche. The other authors declare no competing interests.